News for ARNA Stock

Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23 Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pfizer to Acquire Arena Pharmaceuticals Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Reports Third Quarter Financial Results and Key Program Updates Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4 Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Reports Second Quarter Financial Results and Key Program Updates Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5 Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Steven Schoch Elected to Arena Pharmaceuticals Board of Directors Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE) Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO) Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5 Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23 Arena Pharmaceuticals Announces Changes to Board of Directors Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13 Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial Arena Pharmaceuticals Announces R&D Leadership Transition Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1 Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9 Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis Arena Pharmaceuticals to Participate in Upcoming Investor Conferences Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors Arena Pharmaceuticals to Release Second Quarter 2020 Financial Results and Provide Corporate Update on August 5 Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)